Remond J.A. Fijneman

Dr. Remond J.A. Fijneman

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2019 in Nature
Verified
Journal Article
Closed access
PDF file
SCStephen Cristiano
Stephen Cristiano
ALAlessandro Leal
Alessandro Leal
JPJillian Phallen
Jillian Phallen
JFJacob Fiksel
Jacob Fiksel
VAVilmos Adleff
Vilmos Adleff
VVVictor E. Velculescu
Victor E. Velculescu

16 August 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JPJillian Phallen
Jillian Phallen
MSMark Sausen
Mark Sausen
VAVilmos Adleff
Vilmos Adleff
ALAlessandro Leal
Alessandro Leal
CHCarolyn Hruban
Carolyn Hruban
VVVictor E. Velculescu
Victor E. Velculescu
Noninvasive liquid biopsy analysis of circulating tumor DNA permits direct detection of early-stage cancers.

20 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDimitrios Mathios
Dimitrios Mathios
JJJakob Sidenius Johansen
Jakob Sidenius Johansen
SCStephen Cristiano
Stephen Cristiano
JMJamie E. Medina
Jamie E. Medina
JPJillian Phallen
Jillian Phallen
VVVictor E. Velculescu
Victor E. Velculescu
Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for cancer detection and intervention. Here, we use a machine learning model for detecting tumor-derived cfDNA through genome-wide analyses of cfDNA fragmentation in a prospective study of 365 individuals at risk for lung cancer. We validate the cancer detection model using an independent cohort of 385 non-cancer individuals and 46 lung cancer patients. Combining fragmentation features, clinical risk factors, and CEA levels, followed by CT imaging, detected 94% of patients with cancer across stages and subtypes, including 91% of stage I/II and 96% of stage III/IV, at 80% specificity. Genome-wide fragmentation profiles across ~13,000 ASCL1 transcription factor binding sites distinguished individuals with small cell lung cancer from those with non-small cell lung cancer with high accuracy (AUC = 0.98). A higher fragmentation score represented an independent prognostic indicator of survival. This approach provides a facile avenue for non-invasive detection of lung cancer.

1 February 2019 in Cell
Verified
Journal Article
Closed access
SCSujun Chen
Sujun Chen
VHVincent Huang
Vincent Huang
XXXin Xu
Xin Xu
JLJulie Livingstone
Julie Livingstone
FSFraser Soares
Fraser Soares
HHHousheng Hansen He
Housheng Hansen He

15 October 2003 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
EKEdwin Kanters
Edwin Kanters
MPManolis Pasparakis
Manolis Pasparakis
MGMarion J.J. Gijbels
Marion J.J. Gijbels
MVMonique N. Vergouwe
Monique N. Vergouwe
IPIris Partouns-Hendriks
Iris Partouns-Hendriks
MWMenno de Winther
Menno de Winther
Atherosclerosis is now generally accepted as a chronic inflammatory condition. The transcription factor NF-κB is a key regulator of inflammation, immune responses, cell survival, and cell proliferation. To investigate the role of NF-κB activation in macrophages during atherogenesis, we used LDL receptor–deficient mice with a macrophage-restricted deletion of IκB kinase 2 (IKK2), which is essential for NF-κB activation by proinflammatory signals. These mice showed increased atherosclerosis as quantified by lesion area measurements. In addition, the lesions were more advanced and showed more necrosis and increased cell number in early lesions. Southern blotting revealed that deletion of IKK2 was approximately 65% in macrophages, coinciding with a reduction of 50% in NF-κB activation, as compared with controls. In both groups, the expression of differentiation markers, uptake of bacteria, and endocytosis of modified LDL was similar. Upon stimulation with LPS, production of TNF was reduced by approximately 50% in IKK2-deleted macrophages. Interestingly, we also found a major reduction in the anti-inflammatory cytokine IL-10. Our data show that inhibition of the NF-κB pathway in macrophages leads to more severe atherosclerosis in mice, possibly by affecting the pro- and anti-inflammatory balance that controls the development of atherosclerosis.

1 October 2019 in Molecular Aspects of Medicine
Verified
Journal Article
Open access
MMMaría Marcuello
María Marcuello
VVVeronika Vymetalkova
Veronika Vymetalkova
RNRui P.L. Neves
Rui P.L. Neves
SDSaray Duran-Sanchon
Saray Duran-Sanchon
HVHege Marie Vedeld
Hege Marie Vedeld
MGMeritxell Gironella
Meritxell Gironella
New non-invasive approaches that can complement and improve on current strategies for colorectal cancer (CRC) screening and management are urgently needed. A growing number of publications have documented that components of tumors, which are shed into the circulation, can be detected in the form of liquid biopsies and can be used to detect CRC at early stages, to predict response to certain therapies and to detect CRC recurrence in a minimally invasive way. The analysis of circulating tumor DNA (ctDNA), tumor-derived cells (CTC, circulating tumor cells) or circulating microRNA (miRNA) in blood and other body fluids, have a great potential to improve different aspects of CRC management. The challenge now is to find which types of components, biofluids and detection methods would be the most suitable to be applied in the different steps of CRC detection and treatment. This chapter will provide an up to date review on ctDNA, CTCs and circulating miRNAs as new biomarkers for CRC, either for clinical management or early detection, highlighting their advantages and limitations.